SEC Form 4 · accession 0001209191-16-113722

VERTEX PHARMACEUTICALS INC / MA · VRTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Apr 6, 2016

Accepted (ET)

Apr 8, 2016 · 3:15 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000875320

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Apr 6, 2016	M	5,130	$35.35	A	270,414	D
Common Stock^F2,F3	Apr 6, 2016	S	900	$86.56	D	269,514	D
Common Stock^F2,F4	Apr 6, 2016	S	500	$88.19	D	269,014	D
Common Stock^F2,F5	Apr 6, 2016	S	800	$89.53	D	268,214	D
Common Stock^F2,F6	Apr 6, 2016	S	2,230	$90.60	D	265,984	D
Common Stock^F2,F7	Apr 6, 2016	S	700	$91.12	D	265,284	D
Common Stock	holding	—	—		—	13,286	I	401(k)
Common Stock	holding	—	—		—	122,700	I	Common Stock Held In Trust

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F8	$35.35	Apr 6, 2016	M	5,130	D	—	Jul 19, 2016	Common Stock	5,130	66,700	D

F1Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
F2Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3Open market sales reported on this line occurred at a weighted average price of $86.56 (range $86.30 to $86.81).
F4Open market sales reported on this line occurred at a weighted average price of $88.19 (range $87.69 to $88.48).
F5Open market sales reported on this line occurred at a weighted average price of $89.53 (range $88.95 to $89.88).
F6Open market sales reported on this line occurred at a weighted average price of $90.60 (range $89.95 to $90.92).
F7Open market sales reported on this line occurred at a weighted average price of $91.12 (range $90.99 to $91.41).
F8Fully vested.